UK-based drugmaker, Clinigen, has announced plans to introduce its three cancer drugs in the Kenyan market.
In a statement, Clinigen Group Plc said it had granted Eisai Europe exclusive rights to seek licences from Kenyan authorities for the three brands, Halaven (eribulin), Fycompa (perampanel) and Lenvima (lenvatinib).
